| 摘要: |
| ［摘要］ 目的 探讨Ⅲ～Ⅳ期胸腺瘤患者在行最大程度减瘤手术后进行胸腔热灌注治疗（HITP）的安全性及短期疗效。方法 回顾性分析2022年6月至2025年7月香港大学深圳医院收治的17例Ⅲ～Ⅳ期胸腺瘤患者的临床资料。所有患者均接受最大程度减瘤手术，术后行HITP（46～48 ℃生理盐水，60 min，每间隔24 h一次，共3～5次）。记录围手术期并发症、不良反应及生存情况。随访方式包括门诊复查、电话及微信。结果 16例患者按计划完成3～5次HITP，1例仅完成1次HITP。术后发生明显胸闷不能耐受1例，其余16例主要不良反应为轻度胸闷不适，未见严重心律失常、呼吸衰竭、大出血、吻合口瘘等严重并发症，未出现明显心、肺、肝、肾功能损害。随访1～38个月，所有患者存活，2例ⅣA期患者出现胸腔复发。结论 Ⅲ～Ⅳ期胸腺瘤患者在最大程度减瘤手术后联合HITP具有良好的安全性，不良反应可控，但其长期疗效尚需大样本及长期随访的前瞻性研究进一步验证。 |
| 关键词: 胸腺瘤 胸腔热灌注治疗 减瘤手术 短期疗效 |
| DOI：10.3969/j.issn.1674-3806.2025.10.05 |
| 分类号:R 734.5 |
| 基金项目:深圳市罕见病临床医学研究中心项目（编号：LCYSSQ20220823091402005） |
|
| Analysis on safety and short-term efficacy of postoperative adjuvant hyperthermic intrathoracic perfusion treatment for patients with stages Ⅲ-Ⅳ thymoma |
|
LIU Rutaiyang1,2, PANG Dazhi1,2, PENG Tao1,2, YAN Jinjin1,2, ZHANG Jitian1,2, SHAO Guangqiang1,2, LIU Zhihai1,2, PENG Hao1,2, TANG Ying1,2
|
|
1.Department of Thoracic Surgery, the University of Hong Kong-Shenzhen Hospital, Shenzhen 518053, China; 2.Shenzhen Clinical Research Center for Rare Diseases, Shenzhen 518053, China
|
| Abstract: |
| ［Abstract］ Objective To explore the safety and short-term efficacy of postoperative hyperthermic intrathoracic perfusion treatment(HITP) in patients with stages Ⅲ-Ⅳ thymoma who underwent tumor-reductive surgery to the most extent. Methods A retrospective analysis was conducted on the clinical data of 17 patients with stages Ⅲ-Ⅳ thymoma who were admitted to the University of Hong Kong-Shenzhen Hospital from June 2022 to July 2025. All the patients underwent tumor-reductive surgery to the most extent and received postoperative HITP(with normal saline at 46-48 ℃ for 60 minutes, once every 24 hours with a total of 3-5 treatments). The patients′ perioperative complications, adverse reactions and survival outcomes were recorded. The follow-up methods included outpatient re-examination, phone calls and WeChat communication. Results Among the 17 patients, 16 patients were completed 3 to 5 times of HITP as planned, while 1 patient was only completed 1 time of HITP. One patient experienced unbearable significant chest tightness after surgery, and the major adverse reactions in the other 16 patients were mild chest tightness and discomfort. No severe complications such as severe arrhythmia, respiratory failure, major bleeding and anastomotic fistula were observed. No obvious impairments of heart, lung, liver and kidney functions occurred. During the follow-up period of 1-38 months, all the patients survived, and thoracic recurrence occurred in 2 patients with stage ⅣA thymoma. Conclusion The combined HITP demonstrates good safety and manageable adverse reactions in patients with stages Ⅲ-Ⅳ thymoma who underwent tumor-reductive surgery to the most extent. However, its long-term efficacy still needs further verification through prospective studies with large sample sizes and long-term follow-up. |
| Key words: Thymoma Hyperthermic intrathoracic perfusion treatment(HITP) Tumor-reductive surgery Short-term efficacy |
